Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer42

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer27

Views

Views
February 20251
March 202513
April 20252
May 20250
June 20250
July 20259
August 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore13
United States7
Brazil4
Spain1
Jamaica1
South Africa1
 

Top cities views

Views
São Paulo3
Arlington1
Buffalo1
Concord1
Council Bluffs1
Houston1
Montego Bay1
Pretoria1
Santa Ana1
São Vicente1